Who are Jevtana Kit's main competitors?

Direct comparators (same drug class / molecular target / therapeutic area): Adcetris, Halaven, Taxol, Taxol, Trastuzuma, Polatuzumab.

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/cabazitaxel.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-05-13 · How we verify

Jevtana Kit — Competitive Intelligence Brief

Jevtana Kit (cabazitaxel) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Microtubule Inhibitor. Area: Oncology.

marketed Microtubule Inhibitor Tubulin beta Oncology Live · refreshed every 30 min

Target snapshot

Jevtana Kit (cabazitaxel) — Accord Hlthcare. Cabazitaxel works by binding to tubulin beta, disrupting microtubule formation and preventing cancer cell division.

Comparator set (6 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
Jevtana Kit TARGET	cabazitaxel	Accord Hlthcare	marketed	Microtubule Inhibitor	Tubulin beta	2010-01-01
Adcetris	brentuximab-vedotin	Pfizer	marketed	CD30-directed Immunoconjugate [EPC]	Tubulin beta	2011-01-01
Halaven	ERIBULIN	Eisai	marketed	Microtubule Inhibitor	Tubulin beta	2010-01-01
Taxol	paclitaxel	Pfizer	marketed	Microtubule Inhibitor [EPC]	Tubulin beta-3 chain	1992-01-01
Taxol	nab-paclitaxel	Pfizer	marketed	Microtubule Inhibitor	Tubulin beta-3 chain	1992-01-01
Trastuzuma	Trastuzuma	Fudan University	marketed		Receptor tyrosine-protein kinase erbB-2, Tubulin beta
Polatuzumab	Polatuzumab	National Cancer Institute (NCI)	marketed		B-cell antigen receptor complex-associated protein beta chain, Tubulin beta

Recent regulatory actions (last 90 days)

2026-03-18 — Polatuzumab · FDA · approved · US · National Cancer Institute (NCI)

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

2026-06-10 — Jevtana Kit · 7241907*PED · Compound · US
2026-08-13 — Taxol · 8034375 · Method of Use · US
2026-08-13 — Taxol · 8034375 · US
2026-08-21 — Taxol · 9101543*PED · US
2026-08-21 — Taxol · 8268348*PED · Compound · US
2026-08-21 — Taxol · 7758891*PED · Compound · US
2026-08-21 — Taxol · 9101543*PED · Compound · US
2026-08-21 — Taxol · 8268348*PED · US
2026-08-21 — Taxol · 7758891*PED · US
2027-02-13 — Taxol · 8034375*PED · Compound · US
2027-02-13 — Taxol · 8034375*PED · US
2030-10-27 — Jevtana Kit · 12453712 · Method of Use · US
2030-10-27 — Jevtana Kit · 10583110 · Method of Use · US
2030-10-27 — Jevtana Kit · 10716777 · Method of Use · US
2030-10-27 — Jevtana Kit · 8927592 · Method of Use · US
2031-04-27 — Jevtana Kit · 12453712*PED · Compound · US
2031-04-27 — Jevtana Kit · 8927592*PED · Compound · US
2031-04-27 — Jevtana Kit · 10583110*PED · Compound · US
2031-04-27 — Jevtana Kit · 10716777*PED · Compound · US
2032-03-04 — Taxol · 9393318 · Method of Use · US
2032-03-04 — Taxol · 9597409 · US
2032-03-04 — Taxol · 9393318 · US
2032-03-04 — Taxol · 9597409 · Method of Use · US
2032-09-04 — Taxol · 9393318*PED · Compound · US
2032-09-04 — Taxol · 9597409*PED · Compound · US
2032-09-04 — Taxol · 9393318*PED · US
2032-09-04 — Taxol · 9597409*PED · US
2034-01-12 — Taxol · 9511046 · US
2034-01-12 — Taxol · 9511046 · Method of Use · US
2034-07-12 — Taxol · 9511046*PED · US

Sponsor landscape (Microtubule Inhibitor class)

Pfizer · 2 drugs in this class
Accord Hlthcare · 1 drug in this class
Eisai · 1 drug in this class
R-Pharm Us Llc · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). Jevtana Kit — Competitive Intelligence Brief. https://druglandscape.com/ci/cabazitaxel. Accessed 2026-05-13.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab